{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T11:00:06Z","timestamp":1761390006887,"version":"build-2065373602"},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic lymphocytic leukemia (CLL) treatment choice remains a challenge in the era of molecular biology and targeted therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a bicentric retrospective analysis of the impact of NOTCH1 mutation according to the treatment of CLL patients in real life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 45 patients with NOTCH1 mutation have been reported, including 15 patients treated with FCR BR or DRC regimen and 18 patients with a BTK inhibitor. NOTCH1 mutation is the most frequently occurring molecular abnormality in CLL and is closely associated with poor prognosis but is not used in treatment guidelines unlike TP53 and IGHV. In our study, progression\u2010free survival was significantly longer in CLL patients with NOTCH1 mutation treated by BTK inhibitors compared to immunochemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Routine screening for NOTCH1 mutations could identify patients who may benefit from BTKi treatment. However, the impact of NOTCH1 mutations on combination therapies, such as obinutuzumab\u2010venetoclax or venetoclax\u2010BTKi, is yet to be determined.<\/jats:p>\n                    <jats:p>The authors have confirmed clinical trial registration is not needed for this submission<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70146","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:25:15Z","timestamp":1758900315000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["<i>NOTCH1<\/i>\n                    Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2363-5389","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Ham\u00e9on","sequence":"first","affiliation":[{"name":"Hematology and Cell Therapy Department Tours University Hospital  Tours Centre Val de Loire France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roch","family":"Houot","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy Department Rennes University Hospital  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-9189","authenticated-orcid":false,"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy Department Tours University Hospital  Tours Centre Val de Loire France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Vallet","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy Department Tours University Hospital  Tours Centre Val de Loire France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Lachot","sequence":"additional","affiliation":[{"name":"Biological Hematology Department  Tours France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Ganard","sequence":"additional","affiliation":[{"name":"Hematology Department S\u00e9vign\u00e9 Private Hospital  Cesson\u2010S\u00e9vign\u00e9 Brittany France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Herault","sequence":"additional","affiliation":[{"name":"Biological Hematology Department  Tours France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"De Guibert","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy Department Rennes University Hospital  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9dric","family":"Pastoret","sequence":"additional","affiliation":[{"name":"Biological Hematology Department  Rennes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dartigeas","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy Department Tours University Hospital  Tours Centre Val de Loire France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"G.Defossez S. L.Guyader\u2010Peyrou Z.Uhryet\u00a0al.Estimations nationales de l'incidence et de la mortalit\u00e9 par cancer \u00e0 partir des registres des cancers. (2019)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8762"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379966"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08369.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.175"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1009"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0571-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.251488"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900574"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-429282"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T10:53:43Z","timestamp":1761389623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/jha2.70146"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70146","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"type":"print","value":"2688-6146"},{"type":"electronic","value":"2688-6146"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"2025-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70146"}}